

President's Report

Alan O. Trounson
ICOC Meeting -- February 2010
Agenda Item #5

The California Stem Cell Initiative: Persuasion, Politics and Public Science


J W Adelson & J K Weinberg, APHA Jan 2010

- "The shift of a major focus for stem cell research to California will have a significant effect into the future on the geographic distribution of biological science and biotechnology infrastructure in the United States; on the location of university, biotechnology, and pharmaceutical research and start up firms; and on the investment of venture capital. Evidence for this is the \$300 million the CIRM has invested in stem cell facilities, already leveraged to more than \$1 billion in linked donations."
- "California is host to a steadily growing cadre of world-class scientists, dedicated state-of-the-art facilities, training programs, and support programs... leading from basic stem cell research findings in the laboratory to treatments and cures."


Direct Conversion of Fibroblasts to Functional Neurons by Defined Factors

Vierbuchen, Ostermeier, Pang et al.; Marius Wernig's Lab Stanford University. *Nature* 27th Jan. 2010


- Hypothesized that a panel transcription factors would convert skin cells directly to neurons (iNs)
- Pool of lentiviruses containing 19 genes critical for neurons used to infect skin fibroblasts from TauEGFP KI mice (fluorescent green neurone marker



- The gene *Asd1(Mash1)* could induce green Tuj1+ cells
- The genes *Brn2*, *Brn4* (*Pou3/4*), *Mytl1*, *Zic1* and *Olig2* potentiated the neuron forming property of *Asd1*
- *Asd1, Brn2 and Mytl1* were sufficient to efficiently convert fibroblasts to functional neurons



- The efficiency of conversion to neurons was 1.8% from MEF and 7.8% from TTF iNs
- iNs have normal membrane properties and form functional synapses in vitro




Implications


- Possible that only one gene is really necessary to activate the conversion of fibroblasts to neurons
- Why isn't this a mechanism for neural regeneration in vivo?
- Can this direct conversion be used clinically? –
 cell numbers may be inadequate
- Can other tissues be formed in a more direct conversion using other transcription panels? – note Doug Melton's induction of insulin production using 3 transcription factor conversion of endocrine cells in vivo.


Somatric Sex Reprogramming of Adult Ovaries to Testes by FOXL2 Ablation Uhlenhaut etal., EMBL Germany, MRC Natl Instit Med Res, Baylor Coll Med, Uni Cologne- M Treier Cell 139, 1130, Dec 2009


- In the mouse, the forkhead transcription factor FOXL2, is required to prevent transdifferentiation of an adult ovary to a testis
- Inducible deletion of foxl2 in adult ovarian follicles leads to immediate upregulation of testis-specific genes
- Also reprogramming of follicle granulosa and theca cells into Sertoli
 -like and Leydig-like cell types with testosterone levels comparable
 to normal XY males













R26CreERT2;XX FoxI2^{f/f}



Opposing microRNA families regulate renewal in mouse embryonic stem cells. Melton, Judson & Robert Blelloch UCSF Nature Jan 6 2010


- In the absence DGCR8 protein required for miRNA synthesis mouse ES cells are unable to silence self renewal.
- Let-7 miRNA can suppress self renewal in the absence of DGCR8
- Showed that Let-7 inhibits, whereas ESCC(ES cell cycle regulating miRNA) indirectly activate activate numerous self-renewal genes.
- Inhibition of Let-7 family genes promotes dedifferentiation to iPS cells

Toggle-Switching



Generation purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. Lamba etal. Uni Washington Seattle. PLoS one Jan 20 2010

- Made iPSC from human fibroblasts
- Differentiated iPSCs to retinal progenitors competent to generate photoreceptors
- Purified photoreceptor fraction by FACS)GFP
- On transplantation integrated in mouse retina expressing photoreceptor markers



President's Priorities

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

- VP R&D Search
- Grant issues
 - Californian science leadership on Pre-application processes
 - Data gathering for review of extraordinary petitions
 - Submission of new data prior to review
 - Aggregated percent effort of PIs
 - Industry presence on Grants Working Group
 - Loans and company issues with CIRM regulations
- International agreements and project monitoring
- Patent issues

President's Priorities

- Developing networks between US science and industry
- Continued dialogue with industry and FDA on enhancing success of the stem cell clinical pipeline
- CIRM 2010 External Review
- CIRM economic stimulus issues
- CIRM Development Portfolio Review Dr Olson to present to ICOC April
- Opportunities for pluripotential stem cell clinical trials
- Regulatory pathway issues for stem cell therapies
- CIRM Workshops

Upcoming Grant Reviews



Basic Biology II

- Invited Applications 57
- Application Deadline Dec 8, 2009
- GWG Review February 22-23, 2010
- ICOC April 28-29, 2010

Upcoming RFAs

- Stem Cell Transplantation Immunology
 - Review April 8-9, 2010
 - ICOC June 22-23, 2010
- Research Leadership Awards
 - First application deadline Feb 18, 2010
 - ICOC April 28-29, 2010
- Early Translational II
 - Post RFA Feb 2010
 - Receipt of pre-apps March 18th
 - Full Grant applications June 30th
 - Review Sept 2010
- Tools, Technologies & Bottlenecks
 - Concept clearance Feb 2010
- Clinical
 - Concept clearance March 2010







2010 Program of CIRM Workshops

- CIRM Diversity Workshop, Drew University, LA Feb 26th
- CIRM Grant Writing Webinar March 3rd
- CIRM Grantee Meeting, San Francisco March 3-5th
- Germany/CIRM Science Collaboration, San Francisco March 6th
- Maryland (TEDCO)/CIRM Science Collaboration, MD March 11-12th
- CIRM Consortium/FDA Webinar April 2010
- MRC UK/CIRM SCNT/Parthenogenesis, San Francisco June 13-14th
- ISSCR/CIRM/ISCT Clinical Trials Regulatory Harmonization, San Francisco - June 15th
- ISSCR Annual Meeting, San Francisco June 16-19th
- China/CIRM Science Collaboration, San Francisco June 20-21st
- Spain/CIRM Science Collaboration Q3
- The Netherlands/CIRM Science Collaboration Q4







CIRM Workshop: The Role of CIRM in Enhancing Diversity – February 26, 2010

Goal: Identify how CIRM can enhance diversity in the field of Regenerative Medicine

- Location: Charles Drew University, LA
- Target Audience: CIRM -- To gain a greater understanding of how diversity affects, benefits, and incorporates the fulfillment of CIRM's mission and to use this knowledge as a foundation for the development of funding initiatives that support diversity in regenerative medicine
- Topics:
 - Science and Diversity in Regenerative Medicine
 - Attracting patients and physicians to clinical trials

Proposed Joint UK-CIRM Workshop on SCNT /Parthenogenesis

Workshop on human somatic cell nuclear transfer (SCNT) with UK/MRC

Location: San Francisco - June, 2010

Target audience: CIRM – assess SCNT and parthenogenesis for SCs

Expected attendance: scientific leaders in non-human and human SCNT

Topics:

- •mammalian and non-human primate SCNT lesson learned
- •animal oocyte human nuclear xenotransfer a viable alternative?
- •human SCNT status
- •parthenogenesis a viable road to immune compatible cell lines?
- •SCNT-iPSC comparison in mouse can iPSC replace SCNT?
- mitochondrial diseases SCNT as a potential therapy?

VP R&D Search Update




- Focus of search
 - MD or MD/Ph.D. with clinical development experience (especially pre-clinical, Phase I and II)
 - Proven track record representing development programs before the FDA
 - Excellent collaborator and facilitator
- Candidate backgrounds are focused in the following areas:
 - Biotech/Regenerative Medicine
 - Pharmaceutical

VP R&D Search Update




- The focus is now on 6/(80) potential candidates with meetings undertaken and arranged with senior CIRM staff and some members of the Board
- Three international candidates
- One interstate candidate
- Two Californian candidates




Communications


Don Gibbons Chief Communications Officer

Communications Update





- Bypass what's left of traditional media
- Going face-to-face
 - Slide deck for the board
 - Slide deck for patient groups
 - Town forums
 - Stem Cell Awareness Day
- Grantee communications workshop
- Annual report
- High school curriculum





Los Angeles Times

Date: Location: Circulation (DMA): Type (Frequency):

Page: Keyword: Sunday, January 10, 2010 LOS ANGELES, CA 1,107,074 (2) Newspaper (S) A1,A14 City of Hope

Windfall may speed stem cell cures to patients

Prop. 71 funds are focused on research with near-term goals.

KAREN KAPLAN

Dr. Karen Aboody estimates that she has cured several hundred mice of a cancer of the central nervous system called neuroblastoma.

First she injected them with specialized neural stem cells

For 3½ years, the agency focused on the basic groundwork needed to someday use human embryonic stem cells to replace body parts damaged by injury or disease. Such cures are still far in the future.

Now the institute has a more immediate goal: boosting therapies that are much further along in development and more often rely on less glamorous adult stem cells. It is concentrating its vast financial resources on projects that could

less crucial.

And since Proposition 71 was passed, scientists have created new kinds of stem cells — known as induced pluripotent stem cells — that can be coaxed to form many different types of tissues but are made without harming embryos and thus are eligible for federal funding.

When the institute handed out nearly \$230 million in October to 14 research teams, including Aboody's at City of Hope, it was its largest scientific investment by far. But it came with strings attached: In four years, recipients should have a clinical trial request ready to file with the FDA. Only four of the projects involve embryonic stem cells.

A new emphasis

It is a significant change in direction for an effort originally designed to bolster research on human embryonic stem cells.






GINA FERAZZI Los Angeles Times

RESEARCH: Dr. Karen Aboody saw her sister-in-law suffer from breast cancer that had spread to her brain. She's convinced that stem cell therapy can be more effective and less debilitating. The Proposition 71 money will help her work.










By Scott LaFee, UNION-TRIBUNE STAFF WRITER



EXPLORE FUNDING

See how CIRM grants are distributed across different cell types and disease categories.



CIRM Major Factores Corresponded anno







LATEST PRESS RELEASE

- January 15 2010
 All 12 CIRM Major Facility Projects Moving Forward, Creating Jobs Today And Hope for Cures Tomorrow
- December 10 2009
 CIRM Provides \$11 Million Boost in Funding to Train Stem Cell Scientists
- October 28 2009
 CIRM, the UK and Canada Award more than \$250 Million to Accelerate the Pace of Bringing Stem Cell Therapies to the Clinic

Visit News Room

CIRM FUNDING OF STEM CELL RESEARCH

Our Contributions

- Saving lives: CIRM-funded research has already produced a therapy in clinical trials
- Creating jobs: Our major facilities are generating 13,000 job-years of employment, bringing in \$100 million in tax revenue
- Lowering costs: Therapies funded by CIRM will be available in California at discounted pricing

Read more about benefits to California

Our Funding

- Learn about CIRM rounds of funding
- Apply for funding






NEWS LETTER SIGNUP

Sign up to receive email alerts about CIRM news and events.

ANNOUNCEMENTS


- January 27 2010
 Statement from CIRM Regarding
 Resolution Passed by CFAOC
 Endorsing Certain
 Recommendations of the Little
 Hoover Commission
- January 14 2010
 Statement on American Journal of Public Health Report on CIRM

See all Announcements



CALIFORNIA INSTITUTE FOR REGENE

ATIVE MEDICINE



Proposition 71 Creating Jobs and a New Economic Engine Today Creating Cures Tomorrow Maybe Two Already

name title


date











SF Bay Area






Disease areas funded



Grant distribution: Funding by disease category

Percentages by funding level



Communications Update




- Working with traditional media
- Bypassing what is left of traditional media
- Going face-to-face
 - Slide deck for the board
 - Slide deck for patient groups
 - Town forums
 - Stem Cell Awareness Day
- Communications workshop for grantees
- Annual report
- High school curriculum










STEM CELL

SEPT 23RD 2009

SEPT AWARENESS DAY







ORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Home

MODEL STEM CELL SCIENCE CURRICULUM

View Edit Revisions Track




CIRM model curriculum on stem cell science

The following materials consist of **introductory and summary PowerPoint presentations** and **detailed lessons (modules)** developed by CIRM staff or CIRM-sponsored outreach programs, in collaboration with high school teachers in the Bay Area and San Diego. These detailed lessons comprise the "CIRM model curriculum on stem cell science" as discussed in Senate Bill 471 (Romero and Steinberg), the California Stem Cell and Biotechnology Education and Workforce Development Act of 2009, and signed by the Governor.

These materials are suitable for use in 9th through 12th grade biology, advanced biology, AP biology, chemistry, advanced chemistry, AP chemistry, biotechnology, physiology, anatomy, and government courses.

Jump to sections on this page:

- Introductory lessons on stem cells and regenerative medicine
 - Download presentations
 - Schedule a presenter
- Stem Cell Education Video Series
- Modules on stem cell science
 - Download the stem cell units




















Communications

Amy Adams Communications Manager

Online Communications



Goal: To reach all demographics with information about CIRM's mission and accomplishments

- Web page
- **Facebook**
- YouTube
- CIRMResearch blog
- • Flickr
- Monthly Digest

Communications Messages



- In all online communication we have the same messages
 - CIRM is creating new stem cell-based cures
 - -CIRM is an economic benefit to California

Web page - www.cirm.ca.gov

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Goal: To provide all audiences with useful, accessible content



Web page - www.cirm.ca.gov

Goal: To provide all audiences with useful, accessible content



- •~11,000 unique visitors/month
- •Spend 3:41 on the site
- •View 3.64 pages
- •55% in California
- •109 countries represented

Web page - Education



View Edit Revisions Track

Stem Cell Basics Primer

Get up to speed on stem cell research, from basic information about what the cells are to detailed descriptions of how the cells can improve human health.

Stem cell definitions

The term "stem cell" by itself can be misleading. There are many different types of stem cells, each with very different potential to treat disease. Learn more about the different types of stem cells and their origins.

Creating new types of stem cells

Generating new stem cell lines is a major focus of many CIRM funded researchers. Learn why these new lines are considered so important for the field to move forward.

Stem cells as therapies

Stem cells have the potential to treat a wide range of diseases, including diabetes, neurodegenerative diseases, spinal cord injury, and heart disease. Learn why these cells are such a powerful tool for treating disease as well as what the current hurdles are before new therapies can become available.

Stem cells accelerating basic research

In addition to replacing lost or damaged tissue, stem cells are expected to accelerate the type of basic drug discovery, drug screening, and disease research that is currently underway. Learn more about the many ways stem cells are used in basic medical research.

Stem cell research in California

With funding from CIRM available to California researchers, the state is in a unique position within the United States. Learn more about how CIRM changes the landscape of research in California and about laws in other states.

Common questions about stem cell research


There are a lot of myths about stem cell research, the origin of the stem cells themselves, and the type of work that takes place. Learn what really takes place in stem cell research.





Web page - Interactivity








Web page - Interactivity





Web page - Features






Web page – Fund Allocation



Disease categories

Includes all CIRM grants with a disease focus. Areas of disease impact are designated by percentage of committed funds (left) or by percentage of total grant number (right). Does not include grants with broader impacts, such as those seeking to understand basic mechanisms of stem cell biology or developing new tools and technologies for advancing therapies.



Web page – Grant Information





CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Web page - Going forward



- Increase audience
 - -More links
 - -Better search
 - -Be where people are

Facebook Fan Page



Goal: To create a community of people who are engaged in the daily advances of CIRM



Facebook – Going forward



- Increase fans
- Maintain engagement
- Use Facebook campaigns to involve fans in outreach and education

YouTube

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE


Goal: To educate people about CIRM's accomplishments and the value of stem cell research




YouTube - Our audience



Demographics




YouTube - How viewers find us



YouTube - How viewers find us

Most viewers arrive via YouTube/Google search


Views	33.0% of total
32	12
4	1.6
2	0.8
2	0.8
2	0.8
2	0.8
2	0.8
2	0.8
2	0.8
2	0.8
	32 4 2 2 2 2 2 2 2 2




YouTube – Attention ratings



My Account ▼ / Insight Statistics




YouTube – Attention is high globally




YouTube – How viewers find us

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE


Embedded player (CIRM, grantee, elsewhere)



YouTube – How viewers find us



YouTube – How viewers find us



YouTube - How viewers find us





A Revista

Governo cria conta poupança para bebés - Foi hoje aprovada em conselho de ministros uma das bandeiras socialistas para esta legislatura: a conta-pounpança para recém-nascidos com um depósito inicial de 200 euros

res: Raquel Soares e Tiago Fleming Outeiro Receba a nossa informação:

Fóruns

Encartes

Escreva o seu e-mail

A pastilha que mudou o Mundo!

Dossiers

Pílula faz 50 anos

2010-02-01 Por Jorge Massada

As Ciências


SHARE # 90 EL ...



Foi em 23 de
Junho de 1960
que a Food and
Drug
Administration
(FDA) autorizou a
comercialização
da pílula
anticoncepcional,

após alguns anos de experiências, nomeadamente em mulheres porto-riquenhas. Talvez este organismo americano não soubesse mas acabava de colocar em marcha aquela que seria, provavelmente, a maior revolução de costumes do século passado. Ciência Hoje assinala os 50 anos com um dossier/ fórum.





YouTube – Going forward



- Provide more disease-specific videos
 - These are our most popular videos
 - Parkinson's Disease is the most popular with ~10,000 views to date
- Increase daily views while maintaining high attention ratings


CIRMResearch.blogspot.com

Goal: To highlight progress by CIRM grantees



Flickr – www.flickr.com/photos/cirm

Goal: To show the beauty of stem cell research and provide images to news outlets



Monthly Digest




Goal: To update interested parties about CIRM's activities



Conclusion



- Put information about CIRM where people can find it
- Dispersed information drives people to our site
- More people learn about the value of CIRM and about advances by our grantees



2009-10 Budget Allocation and Expenditure Report


Posted Through December 31, 2009


Chila Silva-Martin, Financial Services Officer

February 3-4, 2010 ICOC Board Meeting

CALIFORNIA INSTITUTE FOR REGENERALIVE MEDICI

Fiscal Year 2009-10 Expenditures Posted Through December 2009





CIRM Operations Summary ICOC - February 2010

John Robson, PhD VP Operations



Financial Projections


CIRM Funding Financial Projections to 6/30/11

Includes: All programs approved by the ICOC

Programs with ICOC concept approval:

- Basic Biology II \$30 million
- Immunology \$30 million
- Research Leadership Awards \$44 million
- Early Translation 2 \$80 million

CIRM Funding Financial Projections to 6/30/11





Major Facilities

Status Report Major Facilities Projects

8 of 12 projects are on schedule:


Grantee Institution	Completion	CIRM Award
Stanford University	July 2010	\$43,578,000
UC San Francisco	June 2010	\$34,862,400
UC Irvine	July 2010	\$27,158,000
USC	July 2010	\$26,972,500
UC Davis	May 2010	\$20,082,400
UC Los Angeles	May 2010	\$19,854,900
UC Berkeley	June 2010	\$20,183,500
UC Santa Barbara	March 2010	\$3,205,800

Stanford University Lorry I. Lokey Stem Cell Research Building






UC Davis Institute for Regenerative Cures



UC Davis Institute for Regenerative Cures



Status Report Major Facilities Projects

3 of 12 projects are delayed 1 year:

Grantee Institution	Completion	CIRM
		Award
San Diego Consortium	June 2011	\$43,000,000
UC Santa Cruz	Nov. 2011	\$7,191,950
UC Merced	Sept. 2011	\$4,359,480

Status Report Major Facilities Projects

1 project is about to begin construction:

Grantee Institution C

Completion

<u>CIRM</u> Award

Buck Institute

March 2012

\$20,500,000

Major Facilities Projects 2010



- Planning programmatic site visits to all projects that received up-front funding.
- Planning technical site visits for other projects.
- Independent audits are due within
 120 days after completion.



Economic Impact

Economic Impact



Develop model to evaluate the economic impact of CIRM's investments including:

- Job creation
- Tax revenues
- Funds leveraged
- Health care savings

Economic Impact



Initial "test study" of Polycythemia Vera and Primary Myelofibrosis

Draft/model will be critiqued by external experts including:

Health Economists Medical Specialists



External Review

External Review

2006 Strategic Plan calls for a review after 3 years by a "blue-ribbon" committee of:

- Scientists
- Clinicians
- Ethicists
- Patient Advocates

Goals of the review are to:

- Measure progress against stated commitments
- Evaluate strategic principles
- Make recommendations for changes

External Review



Building a list of reviewers (5-7):

- Internationally known
- Mostly from outside California

Developing time-line and procedures

Modeling long-range projection for entire \$3 billion authorization

